Updates to the Handbook

• Updated guidance relating to catch-up of meningococcal vaccines. 
• Updated guidance on zoster vaccines in Table. Catch-up schedule for people ≥10 years of age (for vaccines recommended on a population level) 

Guidance on co-administration with other vaccines has been updated to remove guidance on co-administration with Menactra.

Update to remove guidance on co-administration with MenACWY vaccine.

Updates to co-administration with other vaccines to remove guidance on co-administration with MenACWY vaccine.

Introduction of a new vaccine – MenQuadfi and removal of the Menactra vaccine.

Extensive changes to the Recommendation sections and Tables of the chapter including:

• Any person from 6 weeks of age who wants to reduce their risk of meningococcal disease is recommended to receive MenACWY vaccine and MenB vaccine
• Infants and children aged <2 years are strongly recommended to receive MenACWY vaccine
• Infants and children aged <2 years are strongly recommended to receive MenB vaccine
• Healthy adolescents aged 15–19 years are strongly recommended to receive MenACWY vaccine
• Healthy adolescents aged 15–19 years are strongly recommended to receive 2 doses of MenB vaccine
• Aboriginal and Torres Strait Islander people aged 2 months to 19 years are strongly recommended to receive MenACWY vaccine
• All Aboriginal and Torres Strait Islander people aged 2 months to 19 years are strongly recommended to receive MenB vaccine
• People with medical conditions that increase their risk of invasive meningococcal disease are strongly recommended to receive MenACWY and MenB vaccines
• Laboratory workers who frequently handle Neisseria meningitidis are strongly recommended to receive MenACWY and MenB vaccines
• People who travel to areas where meningococcal disease is more common, or who travel to mass gatherings, are strongly recommended to receive MenACWY vaccines
• Adolescents and young adults living in close quarters are strongly recommended to receive MenACWY and MenB vaccines
• Adolescents and young adults who are current smokers are strongly recommended to receive MenACWY and MenB vaccines

Additions to other sections of the chapter include:

• Adverse events - addition of MenQuadfi vaccine

Minor changes in the following section of the chapter include:

• Nature of the disease
• Clinical features
• Epidemiology Transporting, storing and handling vaccines
• Variations from product information

Reference section has been updated.

Updates made to Co-administration with other vaccines to remove information about co-administration of MenACWY vaccines.

Guidance on co-administration with other vaccines has been amended to remove guidance on co-administration with MenACWY vaccines.

Update to remove guidance on co-administration with MenACWY vaccine.

Updates made to co-administration with other vaccines to remove information about co-administration of MenACWY vaccines.

• Update to guidance regarding MenB vaccination for People who have completed cancer therapy and Haematopoietic stem cell transplant recipients.
• Updates to include guidance on recombinant zoster vaccine (Shingrix).

Update to guidance regarding zoster vaccines to include guidance on Shingrix vaccine.

Updated guidance to include recombinant zoster vaccine (Shingrix) in Table. Vaccines that are not routinely recommended in pregnancy: inactivated viral vaccines.

Funding information update

Recommendation updates and additions including

• Recommendation updates for all Recommendations
• Recommendation added for people ages ≥18 years who are immunocompromised
• Recommendation added for People who have previously received Zostavax can receive Shingrix
• Recommendation added for People who have previously received Shingrix need to be assessed on a case-by-case basis to receive Zostavax

Chapter updates have occurred throughout the document in detail, including detailed changes to accommodate the Shingrix vaccine. Sections of particular note are:

• Women who are pregnant or breastfeeding,
• People who are immunocompromised
• Precautions
• Adverse events
• Transporting, storing and handling zoster vaccines
• Variations from product information
• References

Recommendations for skin testing before BCG vaccination have changed. A tuberculin skin test before BCG vaccination is now only recommended in limited circumstances, based on a risk assessment.

Updates to all sections of the Tuberculosis chapter have been made including Recommendations, Vaccines, dosage and administration, Contraindications and precautions, Adverse events, Nature of the disease, Clinical features, Epidemiology, Vaccine information, Transporting, storing and handling vaccines, Public health management and Variations from product information.

Information added to contraindications and precautions regarding vaccination of people with possible IFNAR1 deficiency.

Information added to contraindications and precautions regarding vaccination of people with possible IFNAR1 deficiency.

Information added to contraindications and precautions regarding vaccination of people with possible IFNAR1 deficiency.

Information added to contraindications and precautions regarding vaccination of people with possible IFNAR1 deficiency.

Information added to contraindications and precautions regarding vaccination of people with possible IFNAR1 deficiency.

Information added to contraindications and precautions regarding vaccination of people with possible IFNAR1 deficiency.